Surgical Interventions and Medical Treatments in Treatment-Naive Patients With Acromegaly: Systematic Review and Meta-Analysis

被引:45
作者
Abu Dabrh, Abd Moain [1 ,2 ]
Mohammed, Khaled [2 ]
Asi, Noor [2 ]
Farah, Wigdan H. [2 ]
Wang, Zhen [2 ]
Farah, Magdoleen H. [2 ]
Prokop, Larry J. [3 ]
Katznelson, Laurence [4 ,5 ]
Murad, Mohammad Hassan [1 ,2 ]
机构
[1] Mayo Clin, Div Prevent Occupat & Aerosp Med, Rochester, MN 55905 USA
[2] Mayo Clin, Ctr Sci Hlth Care Delivery, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA
[3] Mayo Clin, Lib Publ Serv, Rochester, MN 55905 USA
[4] Stanford Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Stanford, CA 94305 USA
[5] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA
关键词
ENDOSCOPIC TRANSSPHENOIDAL SURGERY; SECRETING PITUITARY-ADENOMAS; NEWLY-DIAGNOSED PATIENTS; GROWTH-FACTOR-I; OCTREOTIDE-LAR; TUMOR SHRINKAGE; PRIMARY THERAPY; LONG-TERM; LANREOTIDE AUTOGEL; MODERN CRITERIA;
D O I
10.1210/jc.2014-2900
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Acromegaly is usually treated with surgery as a first-line treatment, although medical therapy has also been used as an alternative primary treatment. Objective: We conducted a systematic review and meta-analysis to synthesize the existing evidence comparing these two approaches in treatment-naive patients with acromegaly. Data Sources: This study performed a comprehensive search in multiple databases, including Medline, EMBASE, and Scopus from early inception through April 2014. Study Selection: The study used original controlled and uncontrolled studies that enrolled patients with acromegaly to receive either surgical treatment or medical treatment as their first-line treatment. Data Extraction: Reviewers extracted data independently and in duplicates. Because of the noncomparative nature of the available studies, we modified the Newcastle-Ottawa Scale to assess the quality of included studies. Outcomes evaluated were biochemical remission and change in IGF-1 or GH levels. We pooled outcomes using the random-effects model. Data Synthesis: The final search yielded 35 studies enrolling 2629 patients. Studies were noncomparative series with a follow-up range of 6-360 months. Compared with medical therapy, surgery was associated with a higher remission rate (67% vs 45%; P = .02). Surgery had higher remission rates at longer follow-up periods (>= 24 mo) (66% vs 44%; P = .04) but not the shorter follow-up periods (<= 6 mo) (53% vs 26%; P = .02). Surgery had higher remission rates in the follow-up levels of GH (65% vs 46%; P = .05). In one study, the IGF-1 level was reduced more with surgery compared with medical treatment (-731 mu g/L vs -251 mu g/L; P = .04). Studies in which surgery was performed by a single operator reported a higher remission rate than those with multiple operators (71% vs 47%; P = .002). Conclusions: Surgery may be associated with higher remission rate; however, the confidence in such evidence is very low due to the noncomparative nature of the studies, high heterogeneity, and imprecision.
引用
收藏
页码:4003 / 4014
页数:12
相关论文
共 44 条
[31]   Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly [J].
Karaca, Z. ;
Tanriverdi, F. ;
Elbuken, G. ;
Cakir, I. ;
Donmez, H. ;
Selcuklu, A. ;
Durak, A. C. ;
Dokmetas, H. S. ;
Colak, R. ;
Unluhizarci, K. ;
Kelestimur, F. .
CLINICAL ENDOCRINOLOGY, 2011, 75 (05) :678-684
[32]   Surgical management of GH-secreting pituitary adenomas: An outcome study using modern remission criteria [J].
Kreutzer, J ;
Vance, ML ;
Lopes, MBS ;
Laws, ER .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (09) :4072-4077
[33]  
Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
[34]   Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly [J].
Lombardi, G. ;
Minuto, F. ;
Tamburrano, G. ;
Ambrosio, M. R. ;
Arnaldi, G. ;
Arosio, M. ;
Chiarini, V. ;
Cozzi, R. ;
Grottoli, S. ;
Mantero, F. ;
Bogazzi, F. ;
Terzolo, M. ;
Tita, P. ;
Boscani, P. F. ;
Colao, A. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (03) :202-209
[35]   Preoperative lanreotide treatment for GH-secreting pituitary adenomas:: effect on tumour volume and predictive factors of significant tumour shrinkage [J].
Lucas, T ;
Astorga, R ;
Catalá, M .
CLINICAL ENDOCRINOLOGY, 2003, 58 (04) :471-481
[36]   The Efficacy of Octreotide LAR as Firstline Therapy for Patients with Newly Diagnosed Acromegaly is Independent of Tumor Extension: Predictive Factors of Tumor and Biochemical Response [J].
Luque-Ramirez, M. ;
Portoles, G. R. ;
Varela, C. ;
Albero, R. ;
Halperin, I. ;
Moreiro, J. ;
Soto, A. ;
Casamitjana, R. .
HORMONE AND METABOLIC RESEARCH, 2010, 42 (01) :38-44
[37]   Improvement of acromegaly after octreotide LAR treatment [J].
Ruth Mangupli ;
Aponte Lisette ;
Contreras Ivett ;
Camperos Paul ;
Cruz de los Ríos Victoria ;
Cevallos Jose Luis .
Pituitary, 2003, 6 (1) :29-34
[38]   A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly [J].
Mercado, Moises ;
Borges, Fatima ;
Bouterfa, Hakim ;
Chang, Tien-Chun ;
Chervin, Alberto ;
Farrall, Andrew J. ;
Patocs, Attila ;
Petersenn, Stephan ;
Podoba, Jan ;
Safari, Mitra ;
Wardlaw, Joanna .
CLINICAL ENDOCRINOLOGY, 2007, 66 (06) :859-868
[39]   Octreotide as primary therapy for acromegaly [J].
Newman, CB ;
Melmed, S ;
George, A ;
Torigian, D ;
Duhaney, M ;
Snyder, P ;
Young, W ;
Klibanski, A ;
Molitch, ME ;
Gagel, R ;
Sheeler, L ;
Cook, D ;
Malarkey, W ;
Jackson, I ;
Vance, ML ;
Barkan, A ;
Frohman, L ;
Kleinberg, DL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) :3034-3040
[40]   Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria [J].
Ronchi, CL ;
Varca, V ;
Giavoli, C ;
Epaminonda, P ;
Beck-Peccoz, P ;
Spada, A ;
Arosio, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1377-1382